Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new drug for a tough lung condition just cleared a major hurdle. Roivant's experimental drug mosliciguat significantly reduced pressure in lung blood vessels and improved exercise capacity in patients with pulmonary hypertension linked to interstitial lung disease. The mid-stage trial results sent Roivant shares soaring ~20%, and a late-stage study is already underway.
A promising new option for a hard-to-treat lung condition
Roivant's experimental drug mosliciguat hit its primary and secondary endpoints in a mid-stage trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) — a condition where lung scarring damages blood vessels, forcing the heart to work overtime. The results sent Roivant shares up roughly 20% in premarket trading.
The drug works by reducing pressure and resistance in the lung's blood vessels, and benefits were sustained well beyond the initial 16-week mark, with patients continuing to improve through Week 24. Roivant has already launched a late-stage study targeting ~375 patients worldwide.
By the Numbers
Why it matters: Current PH-ILD treatments are limited, with options like inhaled treprostinil products and off-label PDE5 inhibitors. If mosliciguat succeeds in late-stage trials, it could offer a meaningful new therapy for patients with few alternatives.
